Tech Company Financing Transactions
Corvus Pharmaceuticals Funding Round
Corvus Pharmaceuticals secured a $33.5 million Series A funding round on 7/1/2015. Investors included Adams Street Partners, Novo Ventures and OrbiMed.
Transaction Overview
Company Name
Announced On
7/1/2015
Transaction Type
Venture Equity
Amount
$33,500,000
Round
Series A
Investors
Proceeds Purpose
The company will use the funding proceeds to develop its pipeline of clinical treatments for cancer.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
863 Mitten Rd. 102
Burlingame, CA 94010
USA
Burlingame, CA 94010
USA
Phone
Website
Email Address
Not Recorded
Overview
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Miller
Chief Financial Officer
Leiv Lea
Vice President
Long Kwei
VP - Bus. Development
Daniel Hunt
VP - Bus. Development
William Jones
VP - R & D
Joseph Buggy
VP - R & D
Erik Verner
Browse more venture capital transactions:
Prev: 7/1/2015: Proterra venture capital transaction
Next: 7/1/2015: MoBeam venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs